WUXI BIO (02269.HK) is selling its Irish vaccine facility to Merck for 0.5 billion USD.
WUXI BIO (02269.HK) announced the sale of assets related to the Irish vaccine facility to Merck (MSD International), which includes properties, production equipment, contractual interests related to the Irish vaccine facility as the seller, work-in-progress inventory, and other intangible assets, with a total consideration of approximately 0.5 billion USD (approximately 3.9 billion HKD). It is expected that the asset Trade will not result in any significant gains or losses.
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
WuXi AppTec has reached an agreement with Merck regarding its vaccine factory in Ireland.
Wuxi Haide (WuXi Vaccines) is a wholly-owned subsidiary of WUXI BIO (02269), focusing on the contract customized research and development and production (CDMO) Business of vaccines.
Express News | RPT-WuXi Biologics - Wuxi Vaccines Ireland to Sell All Property and Assets Related to Vaccines Ireland Facility
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between